<code id='1F92E1C715'></code><style id='1F92E1C715'></style>
    • <acronym id='1F92E1C715'></acronym>
      <center id='1F92E1C715'><center id='1F92E1C715'><tfoot id='1F92E1C715'></tfoot></center><abbr id='1F92E1C715'><dir id='1F92E1C715'><tfoot id='1F92E1C715'></tfoot><noframes id='1F92E1C715'>

    • <optgroup id='1F92E1C715'><strike id='1F92E1C715'><sup id='1F92E1C715'></sup></strike><code id='1F92E1C715'></code></optgroup>
        1. <b id='1F92E1C715'><label id='1F92E1C715'><select id='1F92E1C715'><dt id='1F92E1C715'><span id='1F92E1C715'></span></dt></select></label></b><u id='1F92E1C715'></u>
          <i id='1F92E1C715'><strike id='1F92E1C715'><tt id='1F92E1C715'><pre id='1F92E1C715'></pre></tt></strike></i>

          Home / knowledge / focus

          focus


          focus

          author:knowledge    Page View:87643
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In